"Androxal presents several potential advantages including oral dosing, fewer side effects, and...

|By:, SA News Editor

"Androxal presents several potential advantages including oral dosing, fewer side effects, and preservation of fertility," Bank of America says, initiating Repros Therapeutics (RPRX +3.3%) at Buy with a $25 price target. Analyst Steve Byrne sees peak 2022 sales of $450M for the low testosterone treatment, although there are potential risk factors including "a remaining phase 3 read-out" and the company's lack of "commercialization experience."